

Special Issue

Novel Melatonin Based Therapies

Message from the Guest Editors

Melatonin has emerged in the last decade as a promising agent to counteract most of the physiopathological events that trigger several disorders. Most of the beneficial molecular functions exerted by melatonin are due to the following: Its small size and amphiphilic nature allow the molecule to easily diffuse through any membrane, reaching cytosolic, mitochondrial and nuclear compartments. It is a potent scavenger of free radicals, both directly and indirectly, inhibiting the activity of prooxidative enzymes and stimulating antioxidant enzymes through interactions with two high-affinity G protein-coupled receptors.

In this Special Issue, we will focus on the use of melatonin as an adjuvant treatment in a wide variety of diseases, which could be of critical importance for the development of novel therapeutic strategies.

This Special Issue will serve as a forum to bring together researchers of different fields to share advances in the knowledge of the therapeutic uses of melatonin.

Guest Editors

Prof. Dr. Alejandro Romero Martínez

Prof. Dr. Russel J. Reiter

Prof. Dr. Germaine Escames

Deadline for manuscript submissions

closed (30 September 2021)



Diseases

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed



mdpi.com/si/31186

Diseases
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
diseases@mdpi.com

[mdpi.com/journal/
diseases](https://mdpi.com/journal/diseases)





Diseases

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed



[mdpi.com/journal/
diseases](https://mdpi.com/journal/diseases)



About the Journal

Message from the Editor-in-Chief

Diseases is an international, peer-reviewed, open access, multidisciplinary journal that focuses on the latest outstanding research concerning diseases and conditions. Research articles, reviews, and other contents are released on the Internet immediately after acceptance. This journal aims to cover international conferences and symposia as new targets.

Diseases is increasingly gaining acceptance and visibility within scholars, and after only a few years of life, *Diseases* is now also covering specific topics with dedicated special issues. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Omar Cauli

Frailty and Cognitive Impairment—FROG Research Group, University of Valencia, 46010 Valencia, Spain

Author Benefits

High Visibility:

indexed within Scopus, ESCI (Web of Science), PubMed, PMC, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the second half of 2025).